Bradykinin receptor B2

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Retrieved on: 
Saturday, March 18, 2023
Attack, Hereditary angioedema, Safety, Bradykinin receptor B2, Softgel, II, Pain, HAE, Oral, United Kingdom, Conference, Pharmaceutical industry

The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.

Key Points: 
  • The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • The presentation slides will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Retrieved on: 
Friday, February 24, 2023
Translational medicine, Pharmacology, Safety, Bradykinin receptor B2, American Academy, Softgel, Fraunhofer Society, Hereditary angioedema, United Kingdom, AAAAI, Oral, Attack, II, HAE, Berlin, Bradykinin, Poster, Pharmaceutical industry, Dermatology, Immunology

Today, people living with HAE must inject themselves either subcutaneously or intravenously when treating HAE swellings.

Key Points: 
  • Today, people living with HAE must inject themselves either subcutaneously or intravenously when treating HAE swellings.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • Following the data presentation on February 26, the poster and audio recording will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .